Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"CLP290"”.

  1. A Study on the Mechanism of CLP290 Restoration of KCC2 and Neuroprotection after Traumatic Brain Injury

    … mechanism of action for the therapeutic compound CLP290, which our laboratory has previously demonstrated to reverse degradation of the protein potassium-chloride co-transporter 2 (KCC2) and restore neuronal function following modeled traumatic brain injury (TBI) in the rat. The loss of membranous …

    vcu Repository record for A Study on the Mechanism of CLP290 Restoration of KCC2 and Neuroprotection after Traumatic Brain Injury (opens in a new tab)

  2. Effect of KCC2-enhancing prodrug CLP290 on Tat ± morphine treated female mice at the behavioral and molecular levels

    … rescued by oral gavage of KCC2-enhancing prodrug CLP290. We performed similar studies in female DOX-inducible Tat-transgenic mice and administered a ramping dose of morphine to understand the interactive effects with Tat[MM1] . We found that morphine administration increased anxiety-related …

    vcu Repository record for Effect of KCC2-enhancing prodrug CLP290 on Tat ± morphine treated female mice at the behavioral and molecular levels (opens in a new tab)

  3. Enhanced Proteomics Resolves KCC2 as a Novel Therapeutic Target for Traumatic Brain Injury

    … with the KCC2-specific pharmacologic CLP290. Our tested therapeutic window guided by post-translational processing preceding one-day prior to protein loss revealed effective CLP290 restoration of KCC2 localization. We further demonstrated recovery in functional and behavioral …

    vcu Repository record for Enhanced Proteomics Resolves KCC2 as a Novel Therapeutic Target for Traumatic Brain Injury (opens in a new tab)

  4. KCC2: a novel therapeutic target to rescue GABAergic dysfunction and behavioral deficits induced by HIV and opiate use

    … with oral gavage of the prodrug of CLP257, CLP290. Overall, our in vitro and in vivo results demonstrate KCC2 as a promising, novel therapeutic target to alleviate the symptoms associated with HAND ± opiate use.

    vcu Repository record for KCC2: a novel therapeutic target to rescue GABAergic dysfunction and behavioral deficits induced by HIV and opiate use (opens in a new tab)